Premium
Malnutrition–Inflammation Complex Syndrome and Hepatitis C in Maintenance Hemodialysis Patients
Author(s) -
Vlatkovic Vlastimir,
TrbojevicStankovic Jasna,
Stojimirovic Biljana
Publication year - 2009
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2009.00665.x
Subject(s) - medicine , gastroenterology , hemodialysis , dialysis , hepatitis c virus , creatinine , inflammation , malnutrition , uric acid , alanine transaminase , immunology , virus
Protein‐energy malnutrition and inflammation are among the leading causes of poor outcome in hemodialysis patients. Hepatitis C virus (HCV) infection is accompanied by elevated proinflammatory mediators, also found in dialysis patients with malnutrition–inflammation complex syndrome. We aimed to study the rate and characteristics of malnutrition–inflammation complex syndrome (MICS) in hemodialysis patients, especially those with hepatitis C. The study included 147 patients (mean age 55.1 ± 12.9 years), 24.5% of whom were HCV‐positive, undergoing adequate hemodialysis three times a week for the last 52.7 ± 52.5 months. Parameters of nutrition and inflammation were investigated to evaluate MICS. HCV‐positive vs. HCV‐negative patients had significantly higher hematocrit (29.6 ± 4.5 g/dL vs. 28.1 ± 4.3, P < 0.05), uric acid (345.8 ± 96.5 vs. 321.3 ± 118.8 µmol/mL, P < 0.05), aspartate aminotransferase (AST, also known as serum glutamic oxaloacetic transaminase [SGOT]) (23.3 ± 14.9 vs. 17.8 ± 9 U/L, P < 0.008), alanine aminotransferase (ALT, also known as serum glutamic pyruvic transaminase [SGPT]) (41.2 ± 28.7 vs. 26.6 ± 17.1 U/L, P < 0.0003), serum creatinine (980.4 ± 219.1 vs. 888.4 ± 202.9 µmol/mL, P < 0.022), intact parathyroid hormone (329.7 ± 630.5 vs. 110.2 ± 145.3 pg/mL, P < 0.002), malnutrition–inflammation score (7.4 ± 5.2 vs. 5.6 ± 4.1, P < 0.038), and Charlson comorbidity index (4.5 ± 1.5 vs. 4 ± 1.4, P < 0.05). MICS had a prevalence of 20–40% in our study. HCV‐positive patients had a significantly higher prevalence of MICS than HCV‐negative patients (30–40% vs. 20–30%).